2-[1-[3-[4-(dimethylamino)phenyl]prop-2-enoyl]piperidin-4-yl]-2-[[4-(1H-indol-3-yl)cyclohexyl]amino]acetamide | 1352428-63-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 2-[1-[3-[4-(dimethylamino)phenyl]prop-2-enoyl]piperidin-4-yl]-2-[[4-(1H-indol-3-yl)cyclohexyl]amino]acetamide
• CAS: 1352428-63-7
• 化学式: C₃₂H₄₁N₅O₂
• 分子量: 527.71
• InChiKey: MKWNYUAEANRWHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.66
• 重原子数：
  39.0
• 可旋转键数：
  8.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  94.46
• 氢给体数：
  3.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  吲哚 在 盐酸 、 palladium 10% on activated carbon 、 氢气 、 三乙酰氧基硼氢化钠 、 三乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 生成 2-[1-[3-[4-(dimethylamino)phenyl]prop-2-enoyl]piperidin-4-yl]-2-[[4-(1H-indol-3-yl)cyclohexyl]amino]acetamide
  参考文献：
  名称：

  The discovery of novel cyclohexylamide CCR2 antagonists

  摘要：

  As a result of further SAR studies on a piperidinyl piperidine scaffold, we report the discovery of compound 44, a potent, orally bioavailable CCR2 antagonist. While having some in vitro hERG activity, this molecule was clean in an in vivo model of QT prolongation. In addition, it showed excellent efficacy when dosed orally in a transgenic murine model of acute inflammation. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.09.113

文献信息

• The discovery of novel cyclohexylamide CCR2 antagonists
  作者：James C. Lanter、Thomas P. Markotan、Xuqing Zhang、Nalin Subasinghe、Fu-An Kang、Cuifen Hou、Monica Singer、Evan Opas、Sandra McKenney、Carl Crysler、Dana Johnson、Christopher J. Molloy、Zhihua Sui

  DOI：10.1016/j.bmcl.2011.09.113

  日期：2011.12

  As a result of further SAR studies on a piperidinyl piperidine scaffold, we report the discovery of compound 44, a potent, orally bioavailable CCR2 antagonist. While having some in vitro hERG activity, this molecule was clean in an in vivo model of QT prolongation. In addition, it showed excellent efficacy when dosed orally in a transgenic murine model of acute inflammation. (C) 2011 Published by Elsevier Ltd.